Anti CD34 monoclonal antibody/sirolimus - OrbusNeich

Drug Profile

Anti CD34 monoclonal antibody/sirolimus - OrbusNeich

Alternative Names: Combo Dual Therapy Stent; COMBO Plus Dual Therapy Stent; OrbusNeich Combo Stent™

Latest Information Update: 02 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator OrbusNeich
  • Class Anti-infectives; Ischaemic heart disorder therapies; Macrolides; Monoclonal antibodies
  • Mechanism of Action MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Coronary artery restenosis
  • Clinical Phase Unknown Coronary artery disease

Most Recent Events

  • 30 Oct 2017 Efficacy data from the phase II/III Japan-USA HARMONEE registrational trial in Coronary artery restenosis released by OrbusNeich
  • 05 Aug 2015 Phase-II development is ongoing for Coronary restenosis (prevention) in Australia and South Korea
  • 04 Jun 2015 Primary endpoint data from the REMEDEE trial in Coronary artery disease released by OrbusNeich (NCT01874002)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top